Evidence map›Paper›PMID 39900687›Full record

ArticleDermatologie (Heidelberg, Germany)2025

[Intralesional rituximab for refractory granuloma faciale].

Lea Braun, Christoph Löser, Mindaugas Andrulis, Matthias Uhl, Manfred Wolter, Edgar Dippel

Abstract readCase ReportsEnglish Abstract
PubMed Publisher
In one paragraph

Article in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lea BraunHautklinik Ludwigshafen, Klinikum der Stadt Ludwigshafen, Bremserstr. 79, 67063, Ludwigshafen, Deutschland. braunle@klilu.de.
Christoph LöserHautklinik Ludwigshafen, Klinikum der Stadt Ludwigshafen, Bremserstr. 79, 67063, Ludwigshafen, Deutschland.
Mindaugas AndrulisInstitut für Pathologie, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Deutschland.
Matthias UhlKlinik für Strahlentherapie und Radiologische Onkologie, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Deutschland.
Manfred WolterKlinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Frankfurt, Frankfurt am Main, Deutschland.
Edgar DippelHautklinik Ludwigshafen, Klinikum der Stadt Ludwigshafen, Bremserstr. 79, 67063, Ludwigshafen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 60-year-old man presented with refractory granuloma faciale. After unsuccessful treatment with dapsone, hydroxychloroquine, and radiotherapy, treatment with intralesional rituximab was initiated. This led to a steady improvement in the lesions without serious side effects. The case shows that rituximab can be a treatment option for refractory cases of granuloma faciale, especially in the context of IgG 4-related autoimmune disease.

Indexed as

Facial DermatosesGranulomaImmunologic FactorsRituximabHumansInjections, IntralesionalMaleMiddle AgedTreatment OutcomeImmunologic FactorsRituximabAutoimmune diseaseGranuloma eosinophilicum facieiIgG4-related diseaseIntralesional therapyTherapy-resistant

Identifiers

PMID39900687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.